Nurexone Biologic Inc (NRX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 18 | 6 | 6 | 1 | 2 |
| Accounts receivable | 33 | 131 | -96 | 123 | 169 |
| Other Working Capital | 239 | -38 | -98 | 260 | 169 |
| Other Operating Activity | -1,079 | -795 | -635 | 516 | -1,171 |
| Operating Cash Flow | $-789 | $-696 | $-823 | $900 | $-831 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 1 | -2 | -52 | 6 | -9 |
| Other Investing Activity | 0 | 0 | 0 | 0 | -37 |
| Investing Cash Flow | $1 | $-2 | $-52 | $6 | $-46 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -11 | -1 | -8 | 0 | -3 |
| Common Stock Issued | 737 | 0 | 0 | -449 | -1,044 |
| Other Financing Activity | 325 | 0 | 0 | -1,142 | 2,704 |
| Financing Cash Flow | $1,051 | $-1 | $-8 | $-1,591 | $1,657 |
| Exchange Rate Effect | 0 | -9 | 8 | -3 | -47 |
| Beginning Cash Position | 880 | 1,588 | 2,463 | 3,151 | 4,018 |
| End Cash Position | 1,143 | 880 | 1,588 | 2,463 | 3,151 |
| Net Cash Flow | $263 | $-699 | $-883 | $-685 | $780 |
| Free Cash Flow | |||||
| Operating Cash Flow | -789 | -696 | -823 | 900 | -831 |
| Capital Expenditure | N/A | -2 | -52 | N/A | -9 |
| Free Cash Flow | -789 | -698 | -875 | 900 | -840 |